German Covid-19 vaccine only 48% effective in final stage trials

[Thaiger]

A German Covid-19 vaccine that uses the same RNA technology as the Pfizer and Moderna vaccines, has shown an efficacy rate of just 48% in final stage trials. According to a Bangkok Post report, the results for the CureVac vaccine, or CVnCoV, were not a surprise after poor interim data was released earlier in the month. The company has defended the results, pointing out that results varied across age groups and that researchers had to contend with around 15 strains circulating in trial volunteers. By contrast, the Pfizer and Moderna vaccines, which showed around 95% efficacy, only had to deal […]

The post German Covid-19 vaccine only 48% effective in final stage trials appeared first on Thaiger News.

Read the full story

[Stonker]

Interesting to see how ChulaVac (ChulaCov-19) eventually does, as reportedly their team includes the expert behind Pfizer and Moderna.

[King Cotton]

27 minutes ago, Stonker said:

Interesting to see how ChulaVac (ChulaCov-19) eventually does, as reportedly their team includes the expert behind Pfizer and Moderna.

Interesting indeed, especially with it having made the news, via a BKK private hospital's site . . . Chula Vac is COVID-19 vaccine produced in Thailand. It is an mRNA vaccine, similar to Pfizer-BioNTech and Moderna vaccines.

 . . . Another Thai-made vaccine or German, as this header suggests?